This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Feuerstein's Biotech-Stock Mailbag

Thanks for returning to the Biotech Mailbag, where I try my best to answer your biotech investment questions. This week, I'll focus on Cell Genesys (CEGE), Encysive Pharmaceuticals (ENCY), Gilead Sciences (GILD - Get Report) and Alexion Pharmaceuticals (ALXN - Get Report).

I'll kick off the action with a note from Dore S., who writes: "Hey Adam, your faithful herd would probably appreciate an update on Cell Genesys. The company released a Feb. 15 press release that smelled like a subset analysis but has catapulted the stock. Your two cents for all to read would be appreciated."

Dore's sense of smell is pretty good. I'm not a believer in Cell Genesys, and nothing in this latest data presentation for its GVAX prostate cancer vaccine, GVAX-Prostate, compels me to change my mind.

Last week, Cell Genesys reported that researchers analyzing blood samples from prostate cancer patients in a long-ago completed phase II study found two antibody, or immune, responses to GVAX-Prostate that correlated positively with significantly longer survival.

Interesting, except for the fact that in order to find the two antigens responsible for this immune response, the researchers looked at dozens of different antigens -- including some they previously though would be linked to an immune response -- but found nothing.

What this tells us is that Cell Genesys had to go deep-sea fishing with a very large net to find some positive data to report. That's not necessarily a bad thing, but it certainly doesn't prove that GVAX-Prostate is doing what it needs to do most -- helping prostate cancer patients live longer.

Let's not forget that we've seen this game played before. Remember Genitope (GTOP)? It, too, tried to tie an immune response to its MyVax cancer vaccine to a positive clinical benefit for patients. In the end, MyVax turned out to be a dismal failure .

Cell Genesys is running two phase III studies of GVAX-Prostate right now, but that data's not expected until the second half of 2009.

Meantime, Cell Genesys needs to stay visible to investors today. What's one way to do this? Analyze old clinical trials over and over again to scrap together something "new" to say.

That helps put some pop into the stock in the near term, which is what happened over the past week. Shares were up more than 50% at one point.

As I write this Friday, the stock has slipped to around $2.62 after reaching as high as $3.36 on Thursday. Prior to this week, the stock hadn't seen the $3 level since early November.

But I don't think this week's data, or the increase in Cell Genesys' stock price, are indicative of what will happen when we finally see the phase III data on GVAX-Prostate. Like I said, I don't have high hopes for this cancer vaccine, especially in the first phase III trial. In my book, GVAX-Prostate doesn't win.

Pfizer's (PFE - Get Report) decision to buy Encysive Pharmaceuticals for $195 million -- essentially spare change that the drug giant found under the cushions of its reception-area couch -- finally puts to rest to one of the more pitiful biotech sagas in recent memory.

Few companies in this oh-so-fun sector of ours have managed to rack up a record of futility quite like Encysive. There are only a handful of companies that can manage to get turned down three times by the FDA for the same drug. In this case, Encysive was never able to gets its pulmonary arterial hypertension drug Thelin approved in the U.S.

So, now that Pfizer is gobbling them up for a mere $2.35 a share, we can say goodbye and thank Encysive for all the fun we've had at its expense.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GTOP $0.00 20.00%
ALXN $161.13 -1.90%
GILD $100.65 -0.16%
PFE $33.24 0.45%
AAPL $112.03 2.30%


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs